ACROBiosystems is pleased to announce the launch of our new brand, ComboX™, a combination of universal solutions to support biopharmaceutical drug research, development, and manufacturing.

To accelerate and support your research, we aim to provide high-quality and high-performance products whenever and wherever you need them. ComboX™ is a toolbox of essential drug development tools arranged into an easy, one-stop shop for your convenience. These products include Fc receptor proteins, universal antibodies, isotype controls, streptavidin series products, cell culture and activation tools, enzymes, ELISA Kits, and many others. In the future, we plan to expand ComboX™ by developing and launching other universal products that facilitate your drug research applications. We are always here to support you and help foster a more efficient, creative, and productive drug research environment.

Developing new therapeutic drugs is not an easy task; finding ways to help our customers is our motivation behind ComboX™ and our other products. Ensuring quality is an essential value in the process of drug research and development, starting from key reagents to the final therapeutic drug. All ComboX™ products are developed under ACROBiosystems' strict quality control system that is has been certified and audited, under ISO9001, ISO13485, CNAS, and GMP requirements. We ensure that our products excel in product safety, quality, and are cost-effective so that our customers do not need to worry about using our products. Furthermore, we continuously monitor and improve our quality control system to meet and exceed customer expectations, regulatory requirements, and the overall market environment. Through our ComboX TM brand, we seek to provide worry-free, indispensable tools for your biopharmaceutical research and development.

About ACROBiosystems
   ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.